aTyr Pharma (ATYR) announced the outcome of a fourth, pre-planned interim safety analysis conducted by an independent data and safety monitoring board for the ongoing Phase 3 EFZO-FIT study of the company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without any modifications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
Questions or Comments about the article? Write to editor@tipranks.com